

APPLICANTS: Grosse et al.  
U.S.S.N.: 09/976,782

### REMARKS

In response to the Restriction Requirement mailed June 16, 2004, Applicants elect with Group II, Claims 5-14, 39, and 42, drawn to an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide, classified in class 536, subclass 23.1. Further, Applicants elect the nucleotide sequence SEQ ID NO: 15, encoding the polypeptide SEQ ID NO:16.

This election is with traverse. The grounds for traversal are that it would not present an undue burden for the Examiner to examine Groups II, V and XV together, all with regards to a nucleic acid molecule SEQ ID NOS:15, encoding the polypeptide SEQ ID NO: 16. A search of the nucleic acid sequence SEQ ID NO:15 would also identify methods of determining the presence or amount of SEQ ID NO:15 in a sample (Group V) and methods of determining the presence of or predisposition to a disease associated with altered levels of nucleic acid sequence SEQ ID NO:15. Upon approval of this traversal and with regard to elected SEQ ID NO:15, Applicants hereby request that Groups II, V and XV be combined and that claims from Groups V and XV be re-entered and examined.

As a result of this election, the inventorship of this application should be amended to list inventor Ramesh Kekuda, the inventor of elected clone GMAC009404 A (CG54692-05), represented by nucleotide sequence SEQ ID NO:15, encoding the polypeptide SEQ ID NO:16. A Petition and Amendment to Correct Inventorship Under 37 C.F.R. §1.48(b) - Fewer Inventors due to Amendment or Cancellation of Claims ("Petition") has been filed to this effect in a separate submission. A courtesy copy of this Petition is included herewith.


Claims 1-4, 15-38, 40-41, and 43-49 have been canceled without prejudice or disclaimer as drawn to non-elected subject matter. Applicant reserves the right to pursue these claims in a later application. Claims 6 and 10-11 have been canceled. Elected claims 5, 7-9, 12, 14, 39 and 42 are amended herein to track the elected subject matter. Claim 50 has been added. Support for the new and amended pending claims can be found in originally filed claims 1-49 and throughout the specification. No new matter has been added. Upon entry of this amendment, claims 5, 7-9, 12-14, 39, 42 and 50 will be pending.

**APPLICANTS:** Grosse et al.  
**U.S.S.N.:** 09/976,782

### **CONCLUSION**

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that this paper is fully responsive and that the pending claims are in condition for allowance. Such action is respectfully requested. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



DATED: August 16, 2004

Ivor R. Elrifi (Reg. No. 39,529)  
Kristin E. Konzak (Reg. No.: 44,848)  
Attorneys for the Applicants  
c/o MINTZ, LEVIN  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
**Customer Number: 30623**